The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for blockbuster treatments and impressive returns is certain, the connected risks are also signifi… Read More